Metastatic Neuroendocrine Neoplasm: Clinical Trials

2 trials for Metastatic Neuroendocrine Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting. 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 21Active not recruiting 1
Phase 31Active not recruiting 1

Follow Metastatic Neuroendocrine Neoplasm: new trials by email Literature Review of Metastatic Neuroendocrine Neoplasm trials Research Report on Metastatic Neuroendocrine Neoplasm

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
Placebo Administration, Questionnaire Administration, Telotristat Ethyl - Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
Phase 3Active not recruitingM.D. Anderson Cancer Center792021-05-182026-10-15
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
Cabozantinib S-malate, Ipilimumab, Nivolumab - Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)172020-08-062026-09-22

Narrower conditions

Neuroendocrine Tumors (2)  ·  Carcinoma, Neuroendocrine (1)  ·  Small Cell Lung Carcinoma (1)

Broader conditions

Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Germ Cell and Embryonal (2)  ·  Neoplasms, Nerve Tissue (2)  ·  Neuroectodermal Tumors (2)  ·  Adenocarcinoma (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Bronchogenic (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Glandular and Epithelial (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)

Interventions

CTLA-4 Antigen (1)  ·  Ipilimumab (1)  ·  Nivolumab (1)  ·  cabozantinib (1)  ·  telotristat ethyl (1)

Sponsors

M.D. Anderson Cancer Center (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (2)  ·  Canada (1)

Top investigators

Adel Mandl (1)  ·  Cezar A Iliescu, MD (1)

Results publications

PMID 41968073

NIH funding

UM1CA186689 (1), UM1CA186691 (1)